ArticleFrontiers in endocrinology2025
Development and comparison of multivariate diagnostic models for rapidly progressive central precocious puberty in girls: the role of serum osteocalcin.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop a diagnostic prediction model for rapidly progressive central precocious puberty (RP-CPP) and evaluate the contribution of osteocalcin(OC) to the model. Methods: For a total of 411 girls who met the criteria for central precocious puberty were selected. Of these, 219 were included in the training set, 87 in the internal validation set, and 105 in the external validation set. Binary logistic regression was used to construct the model. The model fit and diagnostic accuracy were assessed using the Akaike Information Criterion (AIC), calibration curves, and the area under the receiver operating characteristic curve(AUC). The model was presented in the form of a nomogram. Internal and external validations of the model were performed. Results: Diagnostic models for RP-CPP were developed both with and without the inclusion of OC. Among all models, those that included OC consistently demonstrated smaller AIC values, higher AUC values, and lower prediction error rates. A model incorporating the duration of breast development, serum OC levels, mean ovarian volume, endometrial presence/absence, and breast Tanner staging demonstrated superior performance. The AUC for diagnosing RP-CPP was 0.973, with a sensitivity of 91.6% and specificity of 92.5%. The model performed well in the internal and external validation sets, demonstrating good clinical application value. Conclusion: The inclusion of OC helps improve the predictive performance of the model. For the diagnosis of RP-CPP in girls, a model can be chosen that includes the duration of breast development, serum OC levels, mean ovarian volume, endometrial presence/absence, and breast Tanner staging. However, all samples were from a single center, and multicenter validation is still needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.